The 3rd Bacteriophage Therapy Summit returns! With a new looking speaker line-up and never before seen content, we are excited to continue to unite the community to progress fundamental bacteriophage research into clinically-significant products.
The overuse of antibiotics had led to the development of multi-resistant bacterial strains, most notably ESKAPE pathogens, rendering the use of antibiotics, which in many scenarios are useless. However, bacteriophages may hold the key in overcoming the global antibiotic resistance crisis.
Although the potential use of phage and phage-derived products in a clinical setting is beginning to be understood, there still remains a number of unique challenges associated with this novel therapeutic agent. A developing regulatory landscape, up-scaling of manufacturing processes, and the design of clinical trials are just a few of the roadblocks holding back development.
Bringing together leading drug developers, academics and clinical researchers, our agenda is focused to address the main translation challenges from characterization of phages through to clinical development. This is your opportunity to join your peers to strengthen your product development pipelines and forge new collaborations to unlock the full potential of bacteriophage therapeutics.
CARB-X participants include Richard Alm, Alliance Director.